Aktis Oncology Receives Strong Buy Rating from Raymond James
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Rating Upgrade: Raymond James initiated coverage on Aktis Oncology (AKTS) with a Strong Buy rating and a $40 price target, reflecting market confidence in the company's growth potential based on its radioligand therapy platform.
- Technological Differentiation: Analyst Christopher Raymond highlighted that Aktis' miniprotein-enabled radioligand therapy platform offers significant enhancements in safety, efficacy, and therapeutic flexibility, with differentiation expected to be evident in upcoming clinical trials.
- Asset Expansion Potential: Raymond noted substantial unmodeled upside potential from the expansion of lead programs AKY-1189 and AKY-2519 into other cancer types, along with new radioligands in the pipeline, which further enhances the company's market outlook.
- Strategic Partnership: Aktis secured a research partnership with Eli Lilly worth up to $1.1 billion in early 2024 to develop cancer-targeting radiopharmaceuticals, establishing a solid foundation for the company's long-term growth trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.690
Low
30.00
Averages
31.67
High
34.00
Current: 20.690
Low
30.00
Averages
31.67
High
34.00
About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Oncology Receives Strong Buy Rating from Raymond James
- Rating Upgrade: Raymond James initiated coverage on Aktis Oncology (AKTS) with a Strong Buy rating and a $40 price target, reflecting market confidence in the company's growth potential based on its radioligand therapy platform.
- Technological Differentiation: Analyst Christopher Raymond highlighted that Aktis' miniprotein-enabled radioligand therapy platform offers significant enhancements in safety, efficacy, and therapeutic flexibility, with differentiation expected to be evident in upcoming clinical trials.
- Asset Expansion Potential: Raymond noted substantial unmodeled upside potential from the expansion of lead programs AKY-1189 and AKY-2519 into other cancer types, along with new radioligands in the pipeline, which further enhances the company's market outlook.
- Strategic Partnership: Aktis secured a research partnership with Eli Lilly worth up to $1.1 billion in early 2024 to develop cancer-targeting radiopharmaceuticals, establishing a solid foundation for the company's long-term growth trajectory.
See More
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Aktis Reports Clinical Data for AKY-2519 at ASCO 2026
- Clinical Data Presentation: Aktis Oncology showcased first-in-human imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting, revealing robust tumor uptake and limited normal tissue exposure in metastatic castration-resistant prostate cancer (mCRPC) patients, indicating a potentially differentiated profile in targeted radiopharmaceuticals.
- Trial Design Optimization: These findings informed the ongoing Phase 1b clinical trial design for AKY-2519, which is expected to initiate in the second half of 2026, demonstrating the company's strategic intent to expand clinical development opportunities across various B7-H3 expressing tumor types.
- Safety and Tolerability: The administration of AKY-2519 was generally well tolerated, with no adverse events or infusion-related reactions reported, establishing a solid safety profile that supports further clinical trial advancements.
- Tumor Absorbed Dose Assessment: Predicted absorbed doses of AKY-2519 in mCRPC patients showed favorable therapeutic ranges, particularly in the prostate and metastatic sites, suggesting its potential to address significant unmet medical needs in targeted therapies.
See More
Avidity Partners Acquires Stake in Aktis Oncology
- New Investment Position: Avidity Partners Management disclosed a new position in Aktis Oncology by acquiring 468,566 shares in Q1 2026, with an estimated transaction value of $9.10 million, indicating confidence in the company's future potential.
- Ownership Analysis: This acquisition represents 1.99% of Avidity's reportable AUM as of the quarter-end, highlighting its growing significance within the investment portfolio.
- Market Performance Review: As of May 12, 2026, Aktis Oncology shares were priced at $19.73, down approximately 27% from January's IPO highs but still above the $18 IPO price, reflecting cautious optimism about its future development.
- Financial Overview: Aktis Oncology has a market cap of $1 billion, with TTM revenue of $6.50 million and a net loss of $63.73 million; however, the company maintains a strong balance sheet with about $538.5 million in cash and marketable securities, expected to fund operations into 2029.
See More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion
- Acquisition Scale: UCB's announcement of acquiring Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront, signifies a major consolidation in the biopharmaceutical industry, expected to enhance UCB's market position in autoimmune and inflammatory disease treatments.
- Foundational Background: Candid was formed through the merger of Two River and Vignette Bio, with Two River playing a pivotal role in its founding and early development, showcasing its incubation capabilities and market influence in the biotechnology sector.
- Investment and Strategic Collaboration: Vida Ventures' investment in Candid reflects its strategy of supporting high-quality entrepreneurs, and Candid's successful trajectory illustrates the positive cycle of company creation and strategic collaboration within the Bellco ecosystem, further driving innovation.
- Future Growth Potential: Candid's focus on generating data in China through fast and cost-effective execution is expected to propel its treatment solutions to a global scale, with the collaborative model of Two River and Vida laying a solid foundation for the success of future biotechnology companies.
See More
Aktis Oncology Receives Strong Buy Rating from Raymond James
- Rating Upgrade: Raymond James initiated coverage on Aktis Oncology (AKTS) with a Strong Buy rating and a $40 price target, reflecting market confidence in the company's growth potential based on its radioligand therapy platform.
- Technological Differentiation: Analyst Christopher Raymond highlighted that Aktis' miniprotein-enabled radioligand therapy platform offers significant enhancements in safety, efficacy, and therapeutic flexibility, with differentiation expected to be evident in upcoming clinical trials.
- Asset Expansion Potential: Raymond noted substantial unmodeled upside potential from the expansion of lead programs AKY-1189 and AKY-2519 into other cancer types, along with new radioligands in the pipeline, which further enhances the company's market outlook.
- Strategic Partnership: Aktis secured a research partnership with Eli Lilly worth up to $1.1 billion in early 2024 to develop cancer-targeting radiopharmaceuticals, establishing a solid foundation for the company's long-term growth trajectory.
See More
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Aktis Reports Clinical Data for AKY-2519 at ASCO 2026
- Clinical Data Presentation: Aktis Oncology showcased first-in-human imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting, revealing robust tumor uptake and limited normal tissue exposure in metastatic castration-resistant prostate cancer (mCRPC) patients, indicating a potentially differentiated profile in targeted radiopharmaceuticals.
- Trial Design Optimization: These findings informed the ongoing Phase 1b clinical trial design for AKY-2519, which is expected to initiate in the second half of 2026, demonstrating the company's strategic intent to expand clinical development opportunities across various B7-H3 expressing tumor types.
- Safety and Tolerability: The administration of AKY-2519 was generally well tolerated, with no adverse events or infusion-related reactions reported, establishing a solid safety profile that supports further clinical trial advancements.
- Tumor Absorbed Dose Assessment: Predicted absorbed doses of AKY-2519 in mCRPC patients showed favorable therapeutic ranges, particularly in the prostate and metastatic sites, suggesting its potential to address significant unmet medical needs in targeted therapies.
See More
Avidity Partners Acquires Stake in Aktis Oncology
- New Investment Position: Avidity Partners Management disclosed a new position in Aktis Oncology by acquiring 468,566 shares in Q1 2026, with an estimated transaction value of $9.10 million, indicating confidence in the company's future potential.
- Ownership Analysis: This acquisition represents 1.99% of Avidity's reportable AUM as of the quarter-end, highlighting its growing significance within the investment portfolio.
- Market Performance Review: As of May 12, 2026, Aktis Oncology shares were priced at $19.73, down approximately 27% from January's IPO highs but still above the $18 IPO price, reflecting cautious optimism about its future development.
- Financial Overview: Aktis Oncology has a market cap of $1 billion, with TTM revenue of $6.50 million and a net loss of $63.73 million; however, the company maintains a strong balance sheet with about $538.5 million in cash and marketable securities, expected to fund operations into 2029.
See More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion
- Acquisition Scale: UCB's announcement of acquiring Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront, signifies a major consolidation in the biopharmaceutical industry, expected to enhance UCB's market position in autoimmune and inflammatory disease treatments.
- Foundational Background: Candid was formed through the merger of Two River and Vignette Bio, with Two River playing a pivotal role in its founding and early development, showcasing its incubation capabilities and market influence in the biotechnology sector.
- Investment and Strategic Collaboration: Vida Ventures' investment in Candid reflects its strategy of supporting high-quality entrepreneurs, and Candid's successful trajectory illustrates the positive cycle of company creation and strategic collaboration within the Bellco ecosystem, further driving innovation.
- Future Growth Potential: Candid's focus on generating data in China through fast and cost-effective execution is expected to propel its treatment solutions to a global scale, with the collaborative model of Two River and Vida laying a solid foundation for the success of future biotechnology companies.
See More
